Accelerating Therapeutics for COVID-19
Dr. Dan Hartman, Director of Integrated Development, Bill & Melinda Gates Foundation
Dr. Steven Kern, Deputy Director of Quantitative Sciences, Bill & Melinda Gates Foundation
Dr. Craig Rayner, President of Integrated Drug Development, Certara
Dr. Fran Brown, SVP of Integrated Drug Development, Certara
Date: April 8, 2020
Time: 1:00 pm ET
Duration: 1 hour
The world is now facing an unprecedented and growing challenge with over 1,000,000 cases of and 54,000+ deaths attributed to COVID-19 as of April 3rd.
To accelerate COVID-19 therapeutics to patients worldwide, we need a smarter and more modern approach to drug development. The COVID-19 Therapeutics Accelerator, spearheaded by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard is coordinating R&D efforts to remove barriers to drug development and scale up to address this global pandemic.
Working in close partnership with other Accelerator collaborators, Certara is helping to advance therapeutics for COVID-19 through quantitative and integrated drug development approaches. We are applying our deep experience and expertise in translational and clinical pharmacology, quantitative science, and regulatory strategy to support critical stage-gate decisions, development strategies, clinical trial designs, and dosing optimization for COVID-19.
Please join this webinar to hear about:
- Lessons we can apply from past viral pandemics
- How smarter drug development accelerates therapeutics
- Activities and learnings to date at the COVID-19 Therapeutics Accelerator
- Tools, protocols, and resources for research studies in development
The COVID-19 Therapeutics Accelerator is funded by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard.